ACTINIUM PHARMS INC (ATNM) Drops 10.4% on January 13

Equities Staff |

ACTINIUM PHARMS INC (ATNM) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 10.4% to $1.98, a loss of $-0.2299 per share. Starting at an opening price of $2.19 a share, the stock traded between $1.97 and $2.25 over the course of the trading day. Volume was 706,179 shares over 1,699 trades, against an average daily volume of 631,070 shares and a total float of 42.02 million.

The losses send ACTINIUM PHARMS INC down to a market cap of $83.2 million. In the last year, ACTINIUM PHARMS INC has traded between $6.25 and $1.52, and its 50-day SMA is currently $2.31 and 200-day SMA is $2.44.

Actinium Pharmaceuticals Inc is a biopharmaceutical company which develops drugs for treatment of cancer. It is a development stage company.

ACTINIUM PHARMS INC is based out of New York, NY and has some 12 employees. Its CEO is Kaushik J. Dave.

For a complete fundamental analysis analysis of ACTINIUM PHARMS INC, check out’s Stock Valuation Analysis report for ATNM. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…


Wealthfront is an automated investment service that serves as an alternative to traditional financial advisory services. The company manages a diversified, continually rebalanced portfolio of index funds on their clients’…